Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial.

Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial.

Detalhes bibliográficos
Main Authors:	Mant, D, Perera, R, Gray, A, Rose, P, Fuller, A, Corkhill, A, George, S, Little, L, Regan, S, Mellor, J, Pugh, SA, Northover, J, Weaver, A, Barsoum, G, Tan, LT, Mortensen, N, Scholefield, J, Wasan, H, Ferry, D, Primrose, J
Formato:	Journal article
Publicado em:	2013

Registos relacionados

Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.
Por: Primrose, J, et al.
Publicado em: (2014)

Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial
Por: Pugh, SA, et al.
Publicado em: (2018)

Follow-up after colorectal cancer surgery: Preliminary observational findings from the UK FACS trial
Por: Primrose, J, et al.
Publicado em: (2011)

The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trial.
Por: Shinkins, B, et al.
Publicado em: (2017)

Follow up after colorectal surgery (the FACS trial)
Por: Corkhill, A, et al.
Publicado em: (2004)

The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trial.
Por: Bethany Shinkins, et al.
Publicado em: (2017-01-01)

WHAT IS THE TRUE INCIDENCE OF METACHRONOUS COLORECTAL LIVER METASTASES? EVIDENCE FROM THE UK FACS (FOLLOW-UP AFTER COLORECTAL SURGERY) TRIAL (ISRCTN: 41458548)
Por: Pugh, S, et al.
Publicado em: (2012)

Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial
Por: Pugh, SA, et al.
Publicado em: (2016)

What is the incidence of resectable recurrence after surgery for primary colorectal cancer? Evidence from the UK FACS (Follow-up After Colorectal Surgery) trial
Por: Pugh, S, et al.
Publicado em: (2012)

CEA monitoring in colorectal cancer is not a waste of time.
Por: Mant, D, et al.
Publicado em: (2014)

A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent
Por: Mant, D, et al.
Publicado em: (2017)

Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial
Por: Shinkins, B, et al.
Publicado em: (2018)

Blood CEA levels for detecting recurrent colorectal cancer: A Diagnostic Test Accuracy Review.
Por: Nicholson, B, et al.
Publicado em: (2015)

A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent
Por: David Mant, et al.
Publicado em: (2017-05-01)

What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial.
Por: Shinkins, B, et al.
Publicado em: (2017)

Experiences of patients with false positive results from colorectal cancer screening.
Por: Mant, D, et al.
Publicado em: (1990)

Surveillance for recurrence of colorectal cancer--reply.
Por: Primrose, J, et al.
Publicado em: (2014)

CEA vaccines
Por: Anchit Bhagat, et al.
Publicado em: (2023-12-01)

Ethics of preventive medicine.
Por: Kettner, J, et al.
Publicado em: (1988)

Patient compliance with colorectal cancer screening in general practice.
Por: Mant, D, et al.
Publicado em: (1992)

Performance verification of the MIRI Imager flight model at CEA
Por: Ronayette, S, et al.
Publicado em: (2010)

Delay to CEA
Por: Christopher Nwatuzor, et al.
Publicado em: (2024-01-01)

Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.
Por: Stern, N, et al.
Publicado em: (2005)

Quantitative analysis of mammalian translation initiation sites by FACS‐seq
Por: William L Noderer, et al.
Publicado em: (2014-08-01)

Sorting Out the FACS: A Devil in the Details
Por: William C. Hines, et al.
Publicado em: (2014-03-01)

Selection and characterisation of Affimers specific for CEA recognition
Por: Shazana Hilda Shamsuddin, et al.
Publicado em: (2021-01-01)

Self-administered faecal occult blood tests do not increase compliance with screening for colorectal cancer: results of a randomized controlled trial.
Por: Verne, J, et al.
Publicado em: (1993)

ORGANOMETALLIC PHOTOELECTROCHEMISTRY - OXIDATION OF FAC-TRICARBONYLCHLORO[BIS(DIPHENYLPHOSPHINO)METHANE]MANGANESE(I)
Por: Compton, R, et al.
Publicado em: (1993)

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Por: Reyes Gonzalez-Exposito, et al.
Publicado em: (2019-04-01)

JOSE ROBERTO CEA
Por: La Universidad
Publicado em: (2018-07-01)

Thomas S. Monahan, III, MD, FACS (1975-2019)
Por: Salvatore T. Scali, MD, et al.
Publicado em: (2020-01-01)

Improving the characterization of endothelial progenitor cell subsets by an optimized FACS protocol.
Por: Karin Huizer, et al.
Publicado em: (2017-01-01)

The effect of self-administered faecal occult blood tests on compliance with screening for colorectal cancer: results of a survey of those invited.
Por: Hunter, W, et al.
Publicado em: (1991)

Updating dataset of measurements for the experimental CEA-beam benchmark structure subjected to one stochastic broadband excitation with dataset of measurements for the CEA-beam system subjected to two correlated or uncorrelated broadband random excitations
Por: S. Talik, et al.
Publicado em: (2022-08-01)

What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial
Por: Bethany Shinkins, et al.
Publicado em: (2017-04-01)

Application of a neural network to predict the FAC rate of NPP equipment
Por: A.D. Vishnyakova, et al.
Publicado em: (2016-03-01)

CEA 重组痘苗病毒对 CEA 阳性肿瘤的防治研究
Por: 罗超权, et al.
Publicado em: (2000-01-01)

Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Por: Nolan, K, et al.
Publicado em: (1999)

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
Por: Seung E. Cha, et al.
Publicado em: (2021-01-01)

FAC-1 : FRAMEWORK ALLIANCE CONTRACT
Por: Association of Consultant Architects
Publicado em: (2016)